×

Biotech and Pharmaceuticals Pharmaceuticals

  • ZURICH, June 23- A European Medicines Agency panel recommended on Friday approving Novartis's Kisqali drug, bolstering the Swiss drugmaker's bid to challenge rival Pfizer's Ibrance against tough-to-treat breast cancer. The EMA's Committee for Medicinal Products for Human Use backed Kisqali in combination with hormone therapy as a first-line treatment...

  • SAO PAULO, June 23- The billionaire owners of Uruguay's Mega Pharma SA have hired Jefferies LLC to explore alternatives for Latin America's No. 4 pharmaceutical company, which could include debut bond and stock offerings, two people with knowledge of the matter said. Both the Struengmanns and Mega Pharma, which has $1 billion in annual revenue and 10 factories...

  • AMSTERDAM, June 22- Mylan NV shareholders voted against the generic drugmaker's executive pay policy but re-elected the board at its annual meeting on Thursday despite a shareholder campaign in the wake of a scandal over high prices for its EpiPen emergency allergy treatment. The company did not disclose the vote totals for the directors.

  • Missouri AG: Fraud and deceit by drug makers led to opioid epidemic

    Missouri Attorney General Josh Hawley discusses the state's lawsuit against large pharmaceutical companies about the country's opioid epidemic. CNBC's Meg Tirrell weighs in.

  • AMSTERDAM, June 22- Mylan NV shareholders voted against the generic drugmaker's executive pay policy but re-elected the board at its annual meeting on Thursday despite a shareholder campaign in the wake of a scandal over high prices for its EpiPen emergency allergy treatment. New York City Comptroller Scott Stringer, who oversees the city's pensions and is...

  • June 21- A U.S. jury has ordered Teva Pharmaceutical Industries Ltd to pay GlaxoSmithKline Plc more than $235 million for infringing a patent covering its blood pressure drug Coreg, court documents showed. It awarded GSK $234.1 million in lost profits and said the drug company deserved an additional $1.4 million in royalties. The U.S. Food and Drug...

  • Cramer finds where the real growth is in a split market

    Jim Cramer tracks the stock market's high-growth sectors and explains the battle between value and growth.

  • Finding real growth in a split market

    Jim Cramer tracks the stock market's high-growth sectors and explains the battle between value and growth.

  • WASHINGTON, June 21- The U.S. Food and Drug Administration moved on Wednesday to prevent pharmaceutical companies from "gaming" the system to block or delay entry of generic rivals. FDA Commissioner Scott Gottlieb said in a blog post that the agency plans to hold a public meeting on July 18 to identify ways pharmaceutical companies are using FDA rules to place...

  • WASHINGTON, June 21- The U.S. Food and Drug Administration moved on Wednesday to prevent pharmaceutical companies from "gaming" the system to block or delay entry of generic rivals. FDA Commissioner Scott Gottlieb said in a blog post that the agency plans to hold a public meeting on July 18 to identify ways pharmaceutical companies are using FDA rules to place...

  • Elizabeth Holmes, CEO of Theranos.

    Drugstore chain Walgreens had, at one point, hosted about 40 Theranos blood-testing centers.

  • *Shares up 1.5 percent in London trading. The U.S. Food and Drug Administration green light for Mydayis follows good results for Shire's new hereditary angioedema drug and helps offset the setback of early generic competition to a Shire drug for ulcerative colitis. Shares in Dublin- based Shire rose 1.5 percent by 0800 GMT in London on Wednesday following the...

  • NEW YORK, June 21- Mylan N.V. is best known for producing EpiPen emergency allergy treatments and generic drugs. These refined coal credits were approved by Congress in 2004 in order to incentivize companies to fund production of cleaner coal. Mylan is one of only a few public companies, and the only publicly-traded pharmaceutical maker, that uses these tax...

  • June 20- The U.S. Food and Drug Administration on Tuesday approved Shire Plc's long-acting therapy for attention deficit hyperactivity disorder, adding another treatment to its stock of drugs for the cognitive condition that affects millions of children. Dublin- based Shire's Adderall XR, which manages symptoms for up to 12 hours, is available in generic...

  • LONDON, June 20- Forecasts for global sales of pharmaceuticals have declined for the first time in a decade as continuing pressure on prices in the key U.S. market has caused analysts to moderate revenue expectations, according to a report on Tuesday. Evaluate Pharma, which compiles consensus numbers based on analysts' forecasts, said worldwide drug sales were...

  • Parexel International CEO Josef H. von Rickenbach.

    Parexel will be acquired by Pamplona for $88.10 per share in cash, in a transaction valued at approximately $5 billion, the companies announced Tuesday.

  • ZURICH, June 20- Novartis eye drug RTH258 works as well as a rival product from Regeneron and at less frequent dosing in clinical trials, the Swiss drugmaker said on Tuesday, boosting its shares. The drug, whose generic name is brolucizumab, aims to treat neovascular age-related macular degeneration, the leading cause of severe vision loss and blindness in people...

  • 3 sectors flying high thanks to Washington

    Jim Cramer says tech, bank, and drug stocks are getting a boost from the Trump administration.

  • Tim Cook, CEO, holds an iPad Pro after his keynote address to Apple's annual world wide developer conference (WWDC) in San Jose, California, U.S. June 5, 2017.

    Jim Cramer says tech, bank, and drug stocks are getting a boost from the Trump administration.

  • Cramer pinpoints three sectors flying high thanks to Washington

    Jim Cramer says tech, bank, and drug stocks are getting a boost from the Trump administration.